An update on targeted therapy in metastatic renal cell carcinoma

Giuseppe Lombardi, Fable Zustovich, Martin Donach, Maurizia Dalla Palma, Ornella Nicoletto, Davide Pastorelli

Research output: Contribution to journalArticlepeer-review


An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.

Original languageEnglish
Pages (from-to)240-246
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Issue number3
Publication statusPublished - May 2012


  • Bevacizumab
  • Interferon
  • Renal cancer
  • Sorafenib
  • Sunitinib
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'An update on targeted therapy in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this